ArticleIntegrative cancer therapies
Ze-qi Decoction Inhibits Neutrophil Extracellular Trap Formation to Suppress the Progression and Metastasis of Non-Small Cell Lung Cancer.
Article in Integrative cancer therapies. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Non-small-cell lung cancer (NSCLC) research has focused on complementary and well-established treatments with clear mechanisms and less toxicity. Immune dysregulation is vital in NSCLC progression and metastasis. Ze-qi decoction (ZQD) exhibits therapeutic effects in patients with NSCLC; however, its pharmacodynamic material basis and specific mechanisms remain unclear. In this study, we integrated UPLC-HRMS, pharmacological analysis, and transcriptomic analysis to identify the potential effective components of ZQD and elucidate its intrinsic mechanisms. ZQD exhibited potent anti-NSCLC activity in the mouse subcutaneous tumor model. A total of 297 bioactive compounds were identified in mouse plasma following ZQD administration. Pharmacological analysis revealed liquiritigenin, vibsanin B, and 11-keto-beta-boswellic acid as the potential active ingredients of ZQD and suggested that ZQD exerted anti-NSCLC effects primarily via immunomodulatory and anti-inflammatory pathways. Integrative analysis of network pharmacology and transcriptomics indicated the neutrophil extracellular trap (NET) formation as a key pathway. Further analysis showed that ZQD disrupted the neutrophil recruitment environment by decreasing hypoxia-inducible factor-1α, CD18, and intercellular adhesion molecule-1 levels and downregulating NET-related markers (citrullinated histone H3, myeloperoxidase, and neutrophil elastase). Finally, these results were confirmed in a lung metastasis model. This is the first study designed to analyze the material basis of ZQD responsible for its effect on NSCLC. Our results indicate that the mechanisms of action of ZQD involve impeding neutrophil recruitment and activation, as well as reducing the levels of NETs-related markers. These suggest the potential of ZQD in suppressing NETs formation or release, inhibiting NSCLC progression and metastasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.